Combinatorial Pharmacophore Modeling of Multidrug and Toxin Extrusion Transporter 1 Inhibitors: a Theoretical Perspective for Understanding Multiple Inhibitory Mechanisms

Scientific Reports
Yuan XuMingyue Zheng

Abstract

A combinatorial pharmacophore (CP) model for Multidrug and toxin extrusion 1 (MATE1/SLC47A1) inhibitors was developed based on a data set including 881 compounds. The CP model comprises four individual pharmacophore hypotheses, HHR1, DRR, HHR2 and AAAP, which can successfully identify the MATE1 inhibitors with an overall accuracy around 75%. The model emphasizes the importance of aromatic ring and hydrophobicity as two important structural determinants for MATE1 inhibition. Compared with the pharmacophore model of Organic Cation Transporter 2 (OCT2/ SLC22A2), a functional related transporter of MATE1, the hypotheses of AAAP and PRR5 are suggested to be responsible for their ligand selectivity, while HHR a common recognition pattern for their dual inhibition. A series of analysis including molecular sizes of inhibitors matching different hypotheses, matching of representative MATE1 inhibitors and molecular docking indicated that the small inhibitors matching HHR1 and DRR involve in competitive inhibition, while the relatively large inhibitors matching AAAP are responsible for the noncompetitive inhibition by locking the conformation changing of MATE1. In light of the results, a hypothetical model for inhibiting transporting medi...Continue Reading

References

Oct 5, 1990·Journal of Molecular Biology·S F AltschulD J Lipman
Mar 19, 2004·Journal of Medicinal Chemistry·Thomas A HalgrenJay L Banks
Nov 23, 2005·Bioinformatics·Konstantin ArnoldTorsten Schwede
Dec 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Masato OtsukaYoshinori Moriyama
Oct 13, 2007·Proteins·Pascal BenkertDietmar Schomburg
Dec 17, 2008·Science·Satinder K SinghEric Gouaux
Mar 2, 2010·Nature Reviews. Drug Discovery·UNKNOWN International Transporter ConsortiumLei Zhang
Sep 4, 2010·Biochemical Pharmacology·Takanori NakamuraKen-Ichi Inui
Mar 16, 2012·The Journal of Pharmacology and Experimental Therapeutics·Bethzaida AstorgaStephen H Wright
Oct 23, 2012·Clinical Pharmacology and Therapeutics·K M MorrisseyK M Giacomini
Oct 23, 2012·Clinical Pharmacology and Therapeutics·M J Zamek-GliszczynskiK M Hillgren
Jun 21, 2013·The Journal of Pharmacology and Experimental Therapeutics·Lucy J Martínez-Guerrero, Stephen H Wright

❮ Previous
Next ❯

Datasets Mentioned

BETA
Q96FL8

Software Mentioned

BLAST
PROCHEK
NorM
SWISS
PROCHECK
MODEL
MODELLER
VC
pfMATE
LigPrep

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.